Oppenheimer reiterates Capricor stock rating on FDA data robustness

Oppenheimer has reaffirmed an Outperform rating on Capricor Therapeutics (NASDAQ:CAPR) following a company webinar that reviewed data submitted to the FDA. The rating implies significant upside potential based on the current stock price of $8.10, which has declined 74% over the past six months. The firm highlighted robustness in the HOPE-3 trial’s primary endpoint, with over 600 alternative analyses supporting a 1-point treatment effect over placebo for deramiocel efficacy on upper limb function.

Additionally, integrated analyses from HOPE-2 and HOPE-3 show a 1.29 point PUL 2.0 benefit at Month 12 with a p-value of 0.0087, and favorable LVEF data in the ITT population and patients with cardiomyopathy. Oppenheimer believes the package has a higher likelihood of approval than the current stock price suggests, with a Fair Value of $10.54.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.